Rubicon Research Limited (RUBICON)

Name: Rubicon Research Limited (RUBICON) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-09-20

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant.

Cifras clave

Capitalización bursátil: ₹289 billion
Ingresos (ejercicio cerrado en 2026-03-31): ₹17.3B
Beneficio neto: ₹2.5B
Margen bruto: 66.2%
Margen neto: 14.3%

Ver gráficos interactivos y estados completos →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31
Ingresos totales	₹17.3B	₹12.7B
Beneficio bruto	₹11.5B	₹8.8B
Ingresos operativos (EBIT)	₹3.6B	₹2.2B
Ingresos netos	₹2.5B	—

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de RUBICON. /companies/us/RUBICON

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.